Pay in 4 interest-free payments of $7.26 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
They can be very helpful when appetite is low or whole meals feel too heavy, especially if they help you meet a more realistic protein target
Dual receptor profile simultaneous GIP and GLP-1 receptor engagement in research models 39 amino acid synthetic peptide with C-20 fatty diacid modification for enhanced stability Referenced extensively in peer-reviewed literature across metabolic and endocrine research Useful for comparative studies alongside single GLP-1 agonists and triple receptor compounds Lyophilized format ensures stability and reproducibility across experimental runs Batch and lot identifiers on all labeling for full laboratory documentation compliance Tirzepatide vs
Tirzepatide (LY3298176) is a synthetic 39-amino acid peptide developed as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist
Researchers found that tirzepatide or Mounjaro reduced A1C levels by 2% to 2.3%, while Ozempic (1 mg) led to a 1.9% reduction
For the current Ipamorelin FDA approval status including the 2026 compounding reclassification see our dedicated regulatory page
US$ 28.09
US$ 26.11
US$ 21.32
US$ 21.91
